Opens new purpose-built facility and expands services for highly potent and controlled drugs
Aesica Pharmaceuticals has doubled its development capacity for manufacturing multiple drug products up to Phase III clinical trials at Queenborough, Kent, UK.
The pharmaceutical contract development and manufacturing organisation (CDMO) can now develop and manufacture a product from early formulation development through to clinical manufacture and commercialisation – covering all aspects of a product's lifecycle on the one site.
The company’s highly potent and controlled drugs service offering has been significantly expanded at Queenborough as a result of the new centre.
Previously, Aesica only provided commercial-scale manufacturing capabilities for these drug classifications; it now offers full formulation and development capabilities in these specialist fields. The site handles highly potent drugs for any active up to SafeBridge Category III, together with controlled drugs, with licences for Schedules II–IV.
Ian Muir, Managing Director of Aesica Pharmaceuticals, said: 'We have taken the strategic initiative to ensure that our high capacity Queenborough Development Centre, which doubles our development capacity, combined with our commercial manufacturing capabilities at the facility, provides a complete service offering for formulation, development and product manufacturing for multiple customers.'
He continued: ‘High potency is a key contract services market, with strong growth potential, requiring a mix of highly specialised and advanced technological skills and capabilities. We have set these resources in place and have now taken the strategic initiative to combine them with full clinical and commercial-scale manufacturing capacity in this highly complex field from a single site location.'